Affibody to Participate in the London Life Sciences Week

Regulatory

November 5, 2026

Stockholm, Sweden, November 5, 2026. Affibody Medical AB (“Affibody”), a clinical stage biotechnology company developing next generation radiopharmaceuticals, today announced that management will participate in the London Life Sciences Week, taking place November 15–20, 2026. Affibody will be represented by David Bejker, Chief Executive Officer, and Peter Zerhouni, Chief Financial Officer and Chief Business Officer.

During the week, management will be available for one-on-one meetings with investors and will discuss Affibody’s precision radioligand therapy platform, including the ongoing clinical development of its lead HER2-targeted candidate, ABY-271, and its emerging pipeline of RLT programs for solid tumors.

About Affibody

Affibody is a clinical stage radiopharmaceutical company developing next generation Radioligand Therapies (RLTs) designed to deliver highly selective tumor targeting across a wide range of cancers. Leveraging decades of innovation in Affibody^® molecule discovery and engineering, together with deep understanding of the RLT field, the company is advancing a novel pipeline focused on oncology indications with high unmet medical need. Affibody’s lead RLT candidate, ABY-271, is currently being evaluated in a first-in-human clinical study in HER2-positive metastatic breast cancer.

The Affibody^® platform has also demonstrated clinical value in immunology and inflammation, with multiple programs being advanced through strategic partnerships.

Affibody’s main shareholder, Patricia Industries, is a part of Investor AB.

Further information can be found at: www.affibody.com.

Affibody to Participate in the London Life Sciences Week